Besides adverse events (anemia, neutropenia), drug interactions with immunosuppressive
drugs need to be considered. For example, TLV increases levels of
tacrolimus by approximately 70-fold (Garg 2011). In conclusion, patients with established graft hepatitis should be treated with PEG-IFN/RBV, but at this stage, BOC and TLV should not be used in transplant patients outside clinical trials.